ONCAlert | Upfront Therapy for mRCC
Videos  >  

Investigating Toxicities With Lenvatinib Plus Paclitaxel in Ovarian and Endometrial Cancers

Floor J. Backes, MD
Published Online:4:46 PM, Fri May 17, 2019

Floor J. Backes, MD, associate professor at The Ohio State University Comprehensive Cancer Center, discusses the side effects associated with the combination lenvatinib (Lenvima) plus paclitaxel in patients with recurrent endometrial and platinum-resistant epithelial ovarian cancer.

The toxicities were typical to that of other chemotherapy agents, says Backes. This includes cytopenia, anemia, leukopenia, and some thrombocytopenia. It was mostly the white and red cells that were affected.

In addition, hypertension was the most common grade 3 toxicity, while most other toxicities were grades 1 and 2. Nausea and mucositis were less expected than the other toxicities that were seen, Backes concludes.
Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.